can't believe this is sitting at 16c. Only just above cash backing.Big target - potentially 25% of 100 mill barrels and almost no downside risk and yet no one seems interested.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
